{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:52:49Z","timestamp":1783655569903,"version":"3.55.0"},"reference-count":39,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of oral cenobamate in the treatment of uncontrolled focal epilepsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>The PubMed database and ClinicalTrials.gov were searched using the following terms: cenobamate, Xcopri, and YKP3089.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>Articles published in English between January 2000 and April 2020 related to pharmacology, safety, and clinical trials were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>In a phase 2 trial, cenobamate reduced the median percentage change in seizure frequency from baseline by 56% compared with 22% for placebo ( P &lt; 0.0001). In another phase 2 trial of multiple cenobamate doses, cenobamate reduced seizure frequency by 36% ( P = 0.0071) in the 100-mg group and 55% ( P &lt; 0.0001) in both the 200- and 400-mg groups, compared to 24% with placebo. Adverse effects of cenobamate appear to be similar to those of other antiseizure medications and primarily affect the neurological system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>In patients taking antiseizure medications who continue to have focal seizures, cenobamate has efficacy at multiple doses and is generally well tolerated. Cenobamate may be distinguished from other antiseizure medications by high rates of seizure freedom not seen in previous placebo-controlled trials, which has the potential to significantly improve quality of life. However, despite this efficacy, Drug Reaction with Eosinophilia and Systemic Symptoms may remain a significant concern with cenobamate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As seen in clinical trials, cenobamate as an adjunctive, once-daily treatment represents an efficacious and generally well-tolerated therapy for patients with drug-resistant focal epilepsy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020941113","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T04:00:47Z","timestamp":1594008047000},"page":"318-329","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Cenobamate: A New Adjunctive Agent for Drug-Resistant Focal Onset Epilepsy"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-2273","authenticated-orcid":false,"given":"Christopher T.","family":"Buckley","sequence":"first","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-4073","authenticated-orcid":false,"given":"Olivia R.","family":"Waters","sequence":"additional","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"DeMaagd","sequence":"additional","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"bibr1-1060028020941113","unstructured":"World Health Organization. Epilepsy: a public health imperative: summary. Accessed June 24, 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325440\/WHO-MSD-MER-19.2-eng.pdf?ua=1"},{"key":"bibr2-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200002033420503"},{"key":"bibr3-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3949"},{"key":"bibr4-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00017.x"},{"key":"bibr5-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02586.x"},{"key":"bibr6-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.31400.x"},{"key":"bibr7-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92959-l"},{"key":"bibr8-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.05.007"},{"key":"bibr9-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1994.71.3.1052"},{"key":"bibr10-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7511.2007.00156.x"},{"key":"bibr11-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173117"},{"key":"bibr12-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.769"},{"key":"bibr13-1060028020941113","unstructured":"Xcopri. Package insert. Paramus, NJ. SK Life Science Inc; 2020."},{"issue":"15","key":"bibr14-1060028020941113","first-page":"280","volume":"90","author":"Vernillet L","year":"2018","journal-title":"Neurology"},{"issue":"15","key":"bibr15-1060028020941113","volume":"92","author":"Greene S","year":"2019","journal-title":"Neurology"},{"key":"bibr16-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1344"},{"key":"bibr17-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31827ada88"},{"key":"bibr18-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12499"},{"key":"bibr19-1060028020941113","first-page":"S91","volume":"103","author":"Vernillet L","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"bibr20-1060028020941113","volume-title":"Paper presented at: AES Annual Meeting 2018","author":"Vernillet L"},{"key":"bibr21-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00423.x"},{"key":"bibr22-1060028020941113","volume-title":"Paper presented at: AES Annual Meeting 2018","author":"Sperling M"},{"key":"bibr23-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-020-00305-4"},{"key":"bibr24-1060028020941113","unstructured":"Efficacy and safety of YKP3089 in subjects with treatment resistant partial onset seizures. ClinicalTrials.gov identifier: NCT01397968. Updated November 5, 2019. Accessed January 7, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT01397968"},{"key":"bibr25-1060028020941113","first-page":"438","volume":"14","author":"Chung SS","year":"2014","journal-title":"Epilepsy Curr"},{"key":"bibr26-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(19)30399-0"},{"key":"bibr27-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02522.x"},{"key":"bibr28-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"bibr29-1060028020941113","doi-asserted-by":"crossref","unstructured":"Chung SS, French JA, Krauss G, et al. Long-term safety of adjunctive cenobamate in pateints with uncontrolled focal seizures: open-label extension of a randomized clinical study. Accessed June 24, 2020. https:\/\/n.neurology.org\/content\/94\/15_Supplement\/1039","DOI":"10.1212\/WNL.94.15_supplement.1039"},{"key":"bibr30-1060028020941113","doi-asserted-by":"crossref","unstructured":"Klein P, Krauss GL, Aboumatar S, Kamin M. Long-term efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Accessed June 24, 2020. https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/2421651","DOI":"10.1212\/WNL.94.15_supplement.1008"},{"key":"bibr31-1060028020941113","unstructured":"Safety and pharmacokinetic study of YKP3089 as adjunctive therapy in subjects with partial onset seizures. ClinicalTrials.gov identifier: NCT02535091. Updated February 22, 2019. Accessed January 7, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT02535091"},{"key":"bibr32-1060028020941113","unstructured":"Randomized, double-blind study to evaluate efficacy and safety of cenobamate adjunctive therapy in PGTC seizures. ClinicalTrials.gov identifier: NCT03678753. Updated September 19, 2019. Accessed January 7, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT03678753"},{"key":"bibr33-1060028020941113","unstructured":"Cenobamate open-label extension study for YKP3089C025. ClinicalTrials.gov identifier: NCT03961568. Updated September 20, 2019. Accessed January 7, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT03961568"},{"key":"bibr34-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03047.x"},{"key":"bibr35-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000002864"},{"key":"bibr36-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12212"},{"key":"bibr37-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.198"},{"key":"bibr38-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1113874"},{"key":"bibr39-1060028020941113","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30069-7"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020941113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020941113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020941113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:42Z","timestamp":1777374942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020941113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/1060028020941113"],"URL":"https:\/\/doi.org\/10.1177\/1060028020941113","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]}}}